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                                         Diabetic neuropathy is the most common diabetic 
                                                                                                 
burden. The purpose of this study was evaluation of effect of Semelil (ANGIPARSTM), a new 
herbal drug for treatment of diabetic foot ulcers or diabetic peripheral neuropathy.
         In this double blind clinical trial, 49 type 2 diabetes patients with different degrees 
of neuropathy were evaluated in two groups (ANGIPARSTM and placebo groups). All patients 
were assessed at the start and 12 weeks after treatment, with laboratory tests, United Kingdom 
screening test, Michigan neuropathy screening score, Michigan diabetic neuropathy score, 
                                                                                            
scale.
         Michigan diabetic neuropathy score was decreased notably in ANGIPARSTM group. In 
the nerve conduction study, appropriate meaningful changes were observed in the distal latency 
and amplitude in the motor Ulnar nerve in ANGIPARSTM group.
                                                                             TM in diabetic 
neuropathy treatment and more studies with a larger sample size and longer duration are 
required.
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Diabetic neuropathy is the most common diabetic 
complication associated with a 25-50% lifetime 
risk among diabetic patients. Diabetic peripheral 
neuropathy may be asymptomatic in up to 50% of 
cases, and in 15% symptomatic patients, symptoms 
of neuropathy are severe and require treatment 
                                                    
morbidity, mortality and economic burden. The 
most troublesome and important problem due to 
neuropathy is foot ulcers and subsequent gangrene 
and foot amputation (3) which is responsible for 
50-75% of non traumatic lower limb amputations 
(1,3). Amitriptyline, imipramine, gabapentin, 
duloxetine. have been used for symptomatic therapy 
of peripheral neuropathy but these drugs have 
adverse effects which limit their uses for a long time 
or at high doses (3,4). Therefore more effective and 
appropriate treatment based on the etiological and 
pathogenical factors are being investigated. Diabetic 
neuropathy has a multifactorial pathogenesis with 
different biochemical mechanisms such as increase 
                                                    
neuronal perfusion and consequently interneuron 
hypoxia (1, 5, 6).
Semelil (ANGIPARSTM) is a new herbal drug, an 
extract of                      , for diabetic foot 
ulcers management that has been formulated by 
Iranian scientists in recent years and according to 
the results of pre-clinical and clinical trial (phase 
I-IV) studies, this drug is effective and safe (7-11). 
                                             
as extract of                      (12). Also this drug 
contains compounds such as 7-Hydroxycoumarin 
                                                 
effects and have been shown to be neuroprotective 
(13). Since a possible mechanism for this drug 
is angiogenesis and an increase in tissue blood 
                                                    
ANGIPARSTM improve diabetic neuropathy and 
                                                  
effects of ANGIPARSTM on the treatment of diabetic 
peripheral neuropathy.
       
            
This  study was a 12-weeks randomized double-
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blind placebo-controlled parallel-group clinical trial 
study which was carried out in 49 type 2 diabetic 
patients. The study protocol was approved by the 
ethics committee of Tehran University of Medical 
Sciences.
                     
The patients were selected from those with diabetic 
type 2 which were previously diagnosed according 
to the standard world health organization criteria and 
were referred to Shariati Hospital Diabetes Clinic 
over a period of 9 months (Aug 2008-May 2009). 
After the patient selection, all par  ticipants were fully 
received information about this study and they all 
provided a written informed consent. 
Inclusion criteria were male and females aged 
                                                  
were treated with oral antidiabetic drugs.
                                                     
                                                   
                                                       
coronary artery disease, chronic liver disease, 
                                                    
                                                      
history of allergic drug reactions and pregnancy 
were excluded from the study.
During the primary assessment a detailed patient’s 
past medical history was obtained especially about 
diabetes mellitus duration and drug allergies. A 
comprehensive physical examination of the patients 
was carried out by a trained physician.
Baseline laboratory tests for all subjects were: 
complete blood count, fasting blood sugar, HbA1c, 
                                                        
carried out in the hormone laboratory of Endocrine 
Metabolism Research Institute (EMRI), Shariati 
hospital (Tehran Medical Sciences University). 
Complete blood count was achieved by Sysmex 
(Japan). Biochemical tests were measured by 
enzymatic method using auto analyzer (Parsazmoon 
Co, Iran Kit). HbA1C was measured by Drew-DS5.
The presence and severity of diabetic neuropathy 
was evaluated by following methods.
                                          it is 
a simple questionnaire (score range, 0-9) which 
evaluates the neuropathy as shown in table 1 and 
based on this messurement patients were divided 
                                                
                                                    
severe neuropathy (14).
                                             
Neuropathy was evaluated based on physical 
examination of the patient’s feet in this 8 point 
screening method which is illustrated in table 2. 
Also in a similar manner patients can be divided into 
                                                     
8: naturopathic patient (14, 15).
                                        It has 
three components and score is given for each foot 
separately according to table 3. The maximum score 
of Michigan diabetic neuropathy score is 46 points 
(16).
                                 : It is a simple 
subjective method for assessment of the discomfort 
sensations and feelings intensity, such as foot pain 
due to diabetic neuropathy. It is a straight line which 
has been numbered 0 to10. One end (Number 0) 
means no distress and the other end (Number 10) 
means the worst imaginable discomfort. A Patient 
marks a point on the line based on the amount of 
discomfort that he or she feels (17). 
Other neuropathic evaluations  including nerve 
                             
Burning, numbness, or tingling 2 points 
Fatigue, cramping, or pain 1 point
                           
At the Feet 2 points 
At the Calves 1 point
Elsewhere 0
                                                      
Yes 1 point     
                   
Are nocturnal 2 points 
Are both nocturnal and diurnal 1 point
Are only diurnal 0 
                              
Walking 2 points 
Standing 1 point
Sitting or lying or no relief 0
         United Kingdom screening test.
Right foot Left foot
                                                                    
Absence = 0 Absence = 0
Presence =1 Presence =1
Ulceration
Absence = 0 Absence = 0
Presence =1 Presence =1
                      
Presence = 0 Presence = 0
Present with reinforcement = 0.5 Present with reinforcement = 0.5
Absence = 1 Absence = 1
Vibration sense on the dorsum of the large toe
Presence = 0 Presence = 0
Reduced = 0.5 Reduced = 0.5
Absence =1 Absence =1
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conduction study                               
                                                
plantar surface of the feet) and vibration perception 
thresholds (VPTs) ( by a neurothesiometer at the 
dorsum of each large toe on the interphalangeal 
joint) were determined using standard methods.
                  
The patients were randomized into two groups: A 
(n=25) and B (n=24). In group A, patients received 
oral ANGIPARSTM 100mg capsules and in group B, 
patients received placebo capsules (an inert polymer) 
twice a day for 12 weeks. Both physician and patient 
were blind to treatment. 
                     
The patients were visited monthly to evaluate the 
possible adverse drug reactions. After 12 weeks 
of therapy, all laboratory tests and neurological 
examination were repeated and patients were 
evaluated for possible side effects and drug 
compliance rate (ratio of observed/expected capsule 
consumption).
                    
Results were analysed by SPSS version 14 
software (SPSS .Inc) and data are presented as 
means±standard deviations (SD). Paired t-test was 
used for comparison between results at the start and 
the end of study in any groups and P values less than 
                                               
       
This study as a double blind study was performed 
with 25 (51%) and 24 (49%) patients in the case 
and control groups respectively. There were not 
                                                       
                                                 
cholesterol value (Table 4). 
                                                       
alterations were observed in some parameters in 
some groups as it is shown in table 5 by highlighted 
P value.
Results of neurological examination are shown in 
table 6. These factors were not different at baseline in 
two groups. At the end of study factors didn’t change 
statistically from baseline with the single exception 
of Michigan neuropathy score in the ANGIPARSTM 
group (p= 0.002).
Following study in the sub-analysis phase, patients 
were subdivided according to UK score and 
Michigan  neuropathy screening instrument, then 
changes in other variables were assessed in these 
groups. Table 7 includes only those variables that 
                                       
                                                       
observed by the laboratory evaluations.
          
                                            
ANGIPARSTM for diabetic foot ulcers treatment 
(9-11). Also this medication was expected to be 
effective in diabetic peripheral neuropathy through 
different mechanisms and thus help to diabetic 
foot management since it contains coumarins and 
                                                 
(13). 
An appropriate approach for the assessment of the 
effects of a drug on neuropathy should focus on two 
factors: First, the effect of the drug on the patient’s 
                  
Normal Decreased Absence
Vibration perception at big toe  01 2
             0 1 2
Pinprick on dorsum of great toe painful not painful
02
                       
Normal Moderate Severe Absence
Finger spread 01 2 3
Great toe extension 0 1 2 3
                  0 1 2 3
       
Normal With reinforcement Absence
Biceps brachii 01 2
Triceps brachii 0 1 2
Quadriceps femoris 0 1 2
Achilles 0 1 2
         Michigan diabetic neuropathy score system.Effects of Semelil (ANGIPARSTM) on diabetic peripheral neuropathy 68
Variable Placebo ANGIPARSTM P value
Age (year)* 51±5.5 52.9±5.6 NS
Sex (%)
male 20.8 20 NS
female 79.2 80 NS
BMI (kg/m2)* 29.9±4.8 28.3±3.9 NS
Duration of diabetes (year)* 10.1±10.3 8±4.6 NS
FBS (mg/dl)* 166.4±70.1 162.8±50.6 NS
HbA1C (%)* 7.6±1.8 8.4±1.6 NS
Triglyceride (mg/dl)* 148.3±72.6 209.4±134 0.055
Cholesterol (mg/dl)* 157.7±46.6 185.6±45.8 0.040
                                                                               
         Patient Demographics and Baseline Characteristics.
Nerve Test
Placebo ANGIPARSTM 
P value
ANGIPARS vs. placebo
baseline endpoint Pa baseline endpoint Pb at baseline
Sural
DL 2.99±0.71 3.33±0.77       3.06±0.75 3.18±0.44 0.25 0.76
AM 12.56±8.92 9.67±5.15 0.10 11.52±5.62 11.84±5.99 0.72 0.63
NCV 39.83±11.82 36.5±12.5 0.08 38.44±11.65 38.96±5.36 0.80 0.68
Median
(sensory)
DL 4.02±0.95 4.35±1.27 0.07 4.13±1.04 4.39±1.02       0.70
AM 23.72±14.63 22.62±14.04 0.67 23±13.53 21.19±12.6 0.31 0.86
NCV 37.71±12.72 34.62±12.13      34.96±9.83 32.72±9.51       0.40
Ulnar
(sensory)
DL 3.44±1.04 3.56±1.03 0.11 3.36±.056 3.40±0.40 0.67 0.73
AM 27.33±12.90 30.92±15.65 0.13 25.37±12.97 26.28±11.98 0.72 0.60
NCV 43.33±8.52 42.42±10.78 0.43 43.56±6.26 43.76±5.18 0.84 0.92
Proneal
DL 5.49±2.10 5.46±1.87 0.83 4.90±0.77 4.91±0.78 0.96 0.21
AM 1.55±1.13 1.24±1.01      1.40±0.86 1.28±0.78 0.33 0.60
NCV 39.08±9.98 41.67±5.89 0.08 40.88±4.30 40.60±4.36 0.57 0.41
Median
(motor)
DL 4.94±2.09 4.73±1.98 0.057 4.83±1.27 4.73±1.33 0.30 0.83
AM 5.56±3.84 5.49±2.86 0.92 5.38±3.12 6.10±3.59 0.25 0.86
NCV 58.12±9.65 54.17±7.99      53.76±8.82 53.08±6.57 0.73 0.10
Ulnar
(motor)
DL 3.66±1.24 3.39±0.41 0.21 3.48±0.34 3.28±0.33       0.49
AM 6.10±2.06 6.45±2.47 0.44 6.18±2.11 7.23±1.91       0.89
NCV 52.83±6.67 56.12±7.84       53.56±7.25 57.36±6.43 0.059 0.72
Tibial
DL 5.72±1.59 5.62±1.67 0.55 5.71±0.81 5.56±1.21 0.61 0.99
AM 2.3±1.68 2.47±1.69 0.82 3±2.06 2.89±1.59 0.77 0.20
NCV 37.21±9.68 40.13±5.70 0.07 39.4±4.84 38.8±4.47 0.63 0.32
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symptoms and complaints that were determined by 
UKST and VAS which did not show statistically 
                                                    
of the drug on the common neuropathic process     
prevention of neuropathic advancement and even 
for a therapeutic improvement in the function of 
peripheral nerves. For this purpose NCS and VPT 
                                                
                                                    
                     
Some meaningful results of improvement in NCS 
in the ANGIPARSTM group (Table 5) probably show 
a positive but small effect of ANGIPARSTM in this 
study. In the placebo group distal latency of the Sural 
nerve increased and amplitude of Proneal nerve 
and NCV of median nerve decreased meaningfully 
during the study and these changes are completely 
Test
Placebo ANGIPARSTM P value
ANGIPARS vs. 
placebo at baseline baseline endpoint Pa baseline endpoint Pb
VAS 3.7±3.1 3.1±2.6 0.17 2.7±3.5 2.0±2.9 0.059 0.33
UK 4.1±2.9 3.7±3.1 0.52 3.6±3.5 2.5±3.2 0.08 0.58
Michigan neuropathy screening 2.3±1.8 2.0±1.7 0.17 1.9±1.5 1.3±1.3 0.08 0.37
Michigan neuropathy score 4.9±4.5 4.3±4.5 0.19 4.1±3 2.8±2.9 0.002 0.44
                     9.6±1.0 9.8±0.5 0.10 9.9 ±0.3 9.8±0.5 0.57 0.25
                     9.6±1.1 9.8±0.6 0.10 9.8±0.5 9.9±0.4 0.66 0.39
Vibration perception(R) (Hz) 8.3±4.4 8.5±5.9 0.92 7.6±2.8 7.0±2.9 0.29 0.53
Vibration perception(L) (Hz) 8.2±4.8 8.1±4.9 0.67 7.3±2.6 7.3±2.8 0.97 0.41
                                                                                                                              
                                                                                      
         Baseline and end point results of neurological examination in two groups (Means±SD).
Group
UK score Michigan score
0-4 5-9 0-2 2.5-8
ANGIPARSTM
variable df variable df variable df variable df
DL of Median s. 0.33 DL of Ulnar m. -0.30 DL of Median s. 0.36 DL of Ulnar s.  -0.27
AM of Ulnar m. 0.97 AM of Ulnar m 1.11 NCV of Median s.  -2.83 DL of Ulnar m.4 -0.21
DL of Tibial1 -0.76 AM of Median s.3 -2.40 DL of Ulnar m.  -0.19 Michigan screening -1.71
Michigan score -1.31 AM of Ulnar m 0.93
NCV of Ulnar m.  4.28
Michigan score -1.11
Placebo
DL of Sural 0.31 DL of Sural 0.35 DL of Sural 0.38 AM of Sural -6.27
NCV of Tibial 5.14 NCV of Sural -5.50 DL of Median s.  0.40 AM of Proneal -0.50
NCV of Ulnar m2 5.00 NCV of Median s. -3.44 NCV of Median s.  -3.85 NCV of Ulnar m.  5.00
AM of Proneal -0.34 NCVof Median m -5.46 Michigan screening -0.91
DL of Median m. -0.27 NCV of Tibial 1.75
VAS -1.19
                                                                                                                                              
                                                                                                                                                
                                                                                                                  
in accordant with usual diabetic neuropathy process. 
Although there were some alterations in treatment 
group but they were lower than placebo group and 
                                                       
upper limbs in the ANGIPARSTM group but not 
in the placebo group, distal latency of the Ulnar 
nerve decreased and it’s amplitude increased (these 
                                                  
analysis) that these positive changes can be due to 
systemic effects of this drug.
In spite of reported neuroprotective power of 
                                               
reduction in oxidative stress in the cellular-molecular 
studies (13), results of this study did not reveal 
convincing evidence to support positive effect of 
ANGIPARSTM on diabetic neuropathy and previous 
study also did not show anti-oxidative effect of this Effects of Semelil (ANGIPARSTM) on diabetic peripheral neuropathy 70
drug during 12 weeks treatment (18).
There were some limitations in this study that may 
affect its outcome should be considered. These 
limitations were: Mild degree of neuropathy, good 
sensory nerve of the patients, short duration of 
the study and the lack of performance of biopsy 
                                                     
improvement.
The alterations mentioned above show limited 
                                  TM in diabetic 
neuropathy treatment and suggest that more 
evaluations are required.
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